Skip to main content

RXi Regains Nasdaq Listing

Premium

RXi Pharmaceuticals announced this month that its stock has once again begun trading on the Nasdaq stock market.

"Listing on Nasdaq will help us gain access to a broader institutional investment community and to provide greater liquidity for our shareholders," RXi President and CEO Geert Cauwenbergh said in a statement.

RXi had previously traded on the Nasdaq but lost its listing when it merged with Apthera in 2011. The new company changed its name to Galena, took RXi’s stock listing, and made RXi a subsidiary. RXi was later spun out as a publicly traded independent company again, but traded on the over-the-counter bulletin board.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.